Up-regulation of galectin-3 and Sambucus nigra agglutinin binding site is associated with invasion, metastasis and poor-progression of the gallbladder adenocarcinoma

Hepato-Gastroenterology

Volumn 59, Issue 119, 2012, Pages 2089-2094

  Yang, Le Ping ^a   Jiang, Song ^a   Liu, Jie Qiong ^a   Miao, Xiong Ying ^a   Yang, Zhu Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chronic cholecystitis; Galectin 3; Gallbladder neoplasms; Histocytochemistry; Lectins; Polyp; Sambucus nigra agglutinin

Indexed keywords

AGGLUTININ; GALECTIN 3; SAMBUCUS NIGRA AGGLUTININ; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING SITE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC CHOLECYSTITIS; CYTOCHEMISTRY; FEMALE; GALLBLADDER ADENOCARCINOMA; GALLBLADDER CARCINOMA; GALLSTONE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYP; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VOLUME; UPREGULATION;

ADENOCARCINOMA; ADULT; BINDING SITES; CHI-SQUARE DISTRIBUTION; DNA-BINDING PROTEINS; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; GALECTIN 3; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PLANT LECTINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEINS; RIBOSOME INACTIVATING PROTEINS; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84872074052     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12129     Document Type: Article

References (27)

1. Shimanura T, Sakamoto M, Ino Y, et al.: Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2002; 8(8):2570-2575.
2. Miyazaki T, Hakari R, Kato S, et al.: Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph node. Oncol Rep 2002; 9(6):1307-1312.
3. Kawachi K, Matsushita Y, Yonezawa S, et al.: Galectin-3 expression in various thyroid neoplasma and its possible role in metastasis formation. Hun Pathol 2000; 31(4):428-433.
4. Tsuboi K, Shimura T, Masuda N, et al.: Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res 2007; 27(4B):2289-2296.
5. Htwe TT, Karim N, Wong J, Jahanfar S, Mansur MA: Differential expression of galectin-3 in advancing thyroid cancer cells: a clue towards understanding tumor progression and metastasis . Singapore Med J 2010; 51(11):856-859.
6. Mahmoud LK, Arfaoui A, Khiari M, et al.: Loss of galectin-3 expression in mucinous colorectal carcinomas is associated with 5CpG island methylation in Tunisian patients. App Immunohistochem Mol Morphol 2011; 19(3):258-265.
7. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR: Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol 2001; 159(3):1055-1060.
8. Inagaki Y, Tang W, Guo Q, et al.: Sialoglycoconjugate expression in primary colorectal cancer and metastatic lymph node tissues. Hepato-gastroenterol 2007; 54(73):53-57.
9. Babál P, Janega P, Cerná A, Kholová I, Brabencová E: Neoplastic transformation of the thyroid gland is accompanied by changes in cellular sialylation. Acta Histochem 2006; 108(2):133-140.
10. Tang W, Guo Q, Usuda M, et al.: Histochemical expression of sialoglycoconjugates carcinoma of the papilla of vater. Hepato-gastroenterol 2005; 52(61):67-71.
11. Lin S, Kemmner W, Grigulle S, Schlag PM: Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res 2007; 276(1):101-110.
12. Jayaraman S, Jarnagin WR: Management of gallbladder cancer. Gastroenterol Clin North Am 2010; 39(2):331-342.
13. Yamagiwa H, Tomiyama H, Yoshimura H: Histogenesis of carcinoma of gallbladder. Histological study of serial sections of 1000 cases of resected gallbladder, Rinsho Byori 1986; 34(4):475-480.
14. Roa I, de Aretxabala X, Araya JC, Roa J: Pre-neoplastic lesions in gallbladder cancer. J Surg Oncol 2006; 93(8):615-623.
15. Leonardo E, Valente G, Cappia S, et al.: Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57. Int J Cancer 1994; 57(6):841-846.
16. Khalid H, Yasunaga A, Kishikawa M, Shibata S: Immunohistochemical expression of the estrogen receptor-related antigen (ER-D5) in human intracranial tumors, Cancer 1995; 75(10):2571-2578.
17. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT: Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999; 81(4):519-529.
18. Fernande Z-Aguilar S, Noël JC: Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast. APMIS 2008; 116(1):33-40.
19. Scheffert C, Pour PM, Chaney WG: Localization of galectin-3 in normal and diseased pancreatic tissue. Int J Pancreatol 1998; 23(1):1-9.
20. Janking M, Wongkham C, Sripa B, et al.: Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinomas. Eur J Cancer 2008; 44(4):619-626.
21. Endo K, Kohnoe S, Tsujta E, et al.: Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 2005; 25(4):3117-3121.
22. Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A: Alterations in galectin-3 expressions and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions, Am J Pathol 2004; 165(6):1931-1941.
23. Vierbuchen MJ, Fruechtnich T, Brackrock S, et al.: Quanatitive lectin-hishto chemical and immunohistochemical studies on the occurrence of alpha (2,3)- and alpha (2,6)-linked sialic acid residues in colorectal carcinomas. Relation to clinicopathologic features. Cancer 1995; 76(5):727-735.
24. Dall'olio F, Frere D: Expression of alpha 2, 6-sialylated sugar chain in normal and neoplastic colon tissues. Detection by digoxigenin-conjugated Sambucus nigra agglutinin. Eur J Histochem 1993; 37(3):257-265.
25. Jayaraman S, Jarnagin WR: Management of gallbladder cancer. Gastroenterol Clin North Am 2010; 39(2):331-342.
26. Malik IA: Gallbladder cancer: current status. Expert Opin Pharmacother 2004; 5(6):1271-1277.
27. Tucek S, Tomasek J and Halámkova J: Bile duct malignancies. Klin Onkol 2010; 23(4):231-241.